Homevideos Newsmarket Newsstocks News

    Biocon-Viatris deal: Key highlights for investors from the analyst call

    videos | IST

    Biocon-Viatris deal: Key highlights for investors from the analyst call

    Mini

    There was an incremental downside on Biocon once the analyst call took place at 9 am this morning.

    There was an incremental downside on Biocon once the analyst call took place at 9 am on Monday morning.
    A couple of key concerns that have been brought up with regards to the Biocon-Viatris deal includes the fact regarding valuation; they have paid around 16.7 times EV/EBITDA CY22 estimated and this is versus valuations of 6-7 times for Viatris.
    One of the key concerns is debt, the company will be taking on debt of around $1.2 billion on account of this transaction. So the total debt on books will rise to around $1.5 billion because they have $300 million of debt on their books already.
    The company said that they have the ability to support and finance debt, as per analysts, and the net debt to EBITDA will eventually look to be brought down below three times.
    For more details, watch the accompanying video of CNBC-TV18’s Ekta Batra.
    Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
    next story

      Most Read

      Market Movers

      View All
      CompanyPriceChng%Chng